CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2019--
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company
in the discovery and development of TGF-beta therapeutics to treat
serious and rare diseases, today announced that Habib Dable, President
and Chief Executive Officer, will present an overview of the company
along with its upcoming corporate priorities at the 37th Annual J.P.
Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST
/ 5:00 p.m. EST in San Francisco, California.
In addition, the Company will webcast the question and answer breakout
session immediately following its presentation at 2:30 p.m. PST / 5:30
The live webcast of the presentation and breakout session can be
accessed on the Investors page of the Company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after
the event on the Acceleron website.
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company's
leadership in the understanding of TGF-beta biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005112/en/
Source: Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations
and Corporate Communications
Director, Corporate Communications